secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-076627
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux reports FY2025 net loss $113.6M; cash $966.6M; BMS collaboration with $50M upfront
--------------------------------------------------------------------------------

- Cash and short-term investments $966.6M at Dec 31, 2025, down from $1.03B a year ago.
- R&D expenses $125.9M for FY2025 vs $68.4M; net loss $113.6M vs $69.0M in 2024.
- Entered collaboration with Bristol Myers Squibb for tumor-activated therapeutic; $50M upfront + up to $800M milestones.
- Appointed Dr. William Go as CMO; JANX007/008/011 trials continue enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000119312526076627/0001193125-26-076627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000119312526076627/janx-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-076627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer